In a report released yesterday, Carter Gould from Barclays maintained a Sell rating on Amgen (AMGN – Research Report), with a price target of $230.00. The company’s shares closed yesterday at $285.18.
Gould covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and AbbVie. According to TipRanks, Gould has an average return of 10.7% and a 58.26% success rate on recommended stocks.
In addition to Barclays, Amgen also received a Sell from Robert W. Baird’s Brian Skorney in a report issued on February 7. However, on February 16, Wells Fargo maintained a Buy rating on Amgen (NASDAQ: AMGN).
See today’s best-performing stocks on TipRanks >>
Based on Amgen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $8.2 billion and a net profit of $767 million. In comparison, last year the company earned a revenue of $6.84 billion and had a net profit of $1.62 billion
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amgen (AMGN) Company Description:
Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
Read More on AMGN:
